TY - JOUR
T1 - Daratumumab plus CyBorD for patients with newly diagnosed AL amyloidosis
T2 - Safety run-in results of ANDROMEDA
AU - Palladini, Giovanni
AU - Kastritis, Efstathios
AU - Maurer, Mathew S.
AU - Zonder, Jeffrey
AU - Minnema, Monique C.
AU - Wechalekar, Ashutosh D.
AU - Jaccard, Arnaud
AU - Lee, Hans C.
AU - Bumma, Naresh
AU - Kaufman, Jonathan L.
AU - Medvedova, Eva
AU - Kovacsovics, Tibor
AU - Rosenzweig, Michael
AU - Sanchorawala, Vaishali
AU - Qin, Xiang
AU - Vasey, Sandra Y.
AU - Weiss, Brendan M.
AU - Vermeulen, Jessica
AU - Merlini, Giampaolo
AU - Comenzo, Raymond L.
N1 - Publisher Copyright:
© 2020 by The American Society of Hematology.
PY - 2020/7
Y1 - 2020/7
N2 - Although no therapies are approved for light chain (AL) amyloidosis, cyclophosphamide, bortezomib, and dexamethasone (CyBorD) is considered standard of care. Based on outcomes of daratumumab in multiple myeloma (MM), the phase 3 ANDROMEDA study (NCT03201965) is evaluating daratumumab-CyBorD vs CyBorD in newly diagnosed AL amyloidosis. We report results of the 28-patient safety run-in. Patients received subcutaneous daratumumab (DARA SC) weekly in cycles 1 to 2, every 2 weeks in cycles 3 to 6, and every 4 weeks thereafter for up to 2 years. CyBorD was given weekly for 6 cycles. Patients had a median of 2 involved organs (kidney, 68%; cardiac, 61%). Patients received a median of 16 (range, 1-23) treatment cycles. Treatment-emergent adverse events were consistent with DARA SC in MM and CyBorD. Infusion-related reactions occurred in 1 patient (grade 1). No grade 5 treatment-emergent adverse events occurred; 5 patients died, including 3 after transplant. Overall hematologic response rate was 96%, with a complete hematologic response in 15 (54%) patients; at least partial response occurred in 20, 22, and 17 patients at 1, 3, and 6 months, respectively. Renal response occurred in 6 of 16, 7 of 15, and 10 of 15 patients, and cardiac response occurred in 6 of 16, 6 of 13, and 8 of 13 patients at 3, 6, and 12 months, respectively. Hepatic response occurred in 2 of 3 patients at 12 months. Daratumumab-CyBorD was well tolerated, with no new safety concerns versus the intravenous formulation, and demonstrated robust hematologic and organ responses. This trial was registered at www.clinicaltrials.gov as #NCT03201965.
AB - Although no therapies are approved for light chain (AL) amyloidosis, cyclophosphamide, bortezomib, and dexamethasone (CyBorD) is considered standard of care. Based on outcomes of daratumumab in multiple myeloma (MM), the phase 3 ANDROMEDA study (NCT03201965) is evaluating daratumumab-CyBorD vs CyBorD in newly diagnosed AL amyloidosis. We report results of the 28-patient safety run-in. Patients received subcutaneous daratumumab (DARA SC) weekly in cycles 1 to 2, every 2 weeks in cycles 3 to 6, and every 4 weeks thereafter for up to 2 years. CyBorD was given weekly for 6 cycles. Patients had a median of 2 involved organs (kidney, 68%; cardiac, 61%). Patients received a median of 16 (range, 1-23) treatment cycles. Treatment-emergent adverse events were consistent with DARA SC in MM and CyBorD. Infusion-related reactions occurred in 1 patient (grade 1). No grade 5 treatment-emergent adverse events occurred; 5 patients died, including 3 after transplant. Overall hematologic response rate was 96%, with a complete hematologic response in 15 (54%) patients; at least partial response occurred in 20, 22, and 17 patients at 1, 3, and 6 months, respectively. Renal response occurred in 6 of 16, 7 of 15, and 10 of 15 patients, and cardiac response occurred in 6 of 16, 6 of 13, and 8 of 13 patients at 3, 6, and 12 months, respectively. Hepatic response occurred in 2 of 3 patients at 12 months. Daratumumab-CyBorD was well tolerated, with no new safety concerns versus the intravenous formulation, and demonstrated robust hematologic and organ responses. This trial was registered at www.clinicaltrials.gov as #NCT03201965.
UR - http://www.scopus.com/inward/record.url?scp=85086737056&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85086737056&partnerID=8YFLogxK
U2 - 10.1182/BLOOD.2019004460
DO - 10.1182/BLOOD.2019004460
M3 - Article
C2 - 32244252
AN - SCOPUS:85086737056
SN - 0006-4971
VL - 136
SP - 71
EP - 80
JO - Blood
JF - Blood
IS - 1
ER -